Lantern Pharma Seeks Approval to Double Authorized Shares and Issue 3.67M Warrant Shares
LTRN is trading near its 52-week low of $0.83 (0.0% above the low).
Summary
Lantern Pharma's preliminary proxy seeks stockholder approval to double authorized shares to 50 million and issue up to 3.67 million shares upon warrant exercise, providing needed capital but adding dilution.
Key Events · Corporate Governance and Compliance · LTRN
-
Authorized Share Increase to 50 Million
Proposal 2 seeks to increase authorized common stock from 25 million to 50 million shares. As of October 5, 2026, only 281,597 authorized shares remain unissued and unreserved, leaving no headroom for the warrant exercise or future financing.
-
Warrant Share Issuance Approval
Proposal 4 seeks approval for issuance of up to 3,669,725 shares upon exercise of Purchase Warrants sold to an institutional investor on September 28, 2026, at an exercise price of $1.09 per share. Full exercise would raise approximately $4.0 million in gross proceeds.
-
Nasdaq Listing Rule 5635(d) Compliance
The warrant share issuance requires stockholder approval because it exceeds 20% of outstanding shares at a price below the Nasdaq minimum price. The company received a delisting notice on October 1, 2026 for failing to maintain the $35 million minimum market value.
-
Equity Incentive Plan Increase
Proposal 3 seeks to increase the Equity Incentive Plan share reserve by 250,000 shares to 2,114,680 shares. Only 175,633 shares remain available for future grants as of the proxy date.
Analysis · LTRN · Life Sciences
Lantern Pharma is asking stockholders to approve a doubling of authorized common stock to 50 million shares and the issuance of up to 3.67 million shares upon exercise of purchase warrants sold in the September 2026 offering. The company has only 281,597 unissued and unreserved authorized shares remaining, so the increase is necessary to cover the warrant exercise and future financing. The warrant approval is required under Nasdaq Listing Rule 5635(d) because the potential issuance exceeds 20% of outstanding shares at a price below the minimum price. If approved, full warrant exercise would raise approximately $4.0 million in gross proceeds at $1.09 per share, but would dilute existing stockholders. The company is trading near its 52-week low and recently received a Nasdaq delisting notice for failing to maintain the $35 million minimum market value, making this capital-raising and share-authorization vote critical to its continued listing and operations.
How filings like this one have moved
In the 30 days to Oct 8, 2026, 28.6% of the 1679 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LTRN was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.4M. The 52-week trading range was $0.83 to $4.70. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.